Editorial Note: Gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) is a highly prevalent gastrointestinal malignancy worldwide. Most patients are diagnosed at an advanced stage when curative treatment is no longer feasible, resulting in poor overall prognosis and substantial unmet clinical needs with current therapeutic regimens. FGFR2b represents a key exploratory target in gastric cancer targeted therapy. Previous phase 3 registrational trials of the targeted agent bemarituzumab have yielded inconsistent efficacy outcomes, and the definition of its precise benefit population has long been a focus of the field.

At the 2026 European Society for Medical Oncology (ESMO) Congress, Prof. Zev A. Wainberg from the University of California, Los Angeles (UCLA) Medical Center presented the results of an exploratory biomarker analysis from two phase 3 studies, FORTITUDE-101 and FORTITUDE-102 (Abstract No. 2883RO). This analysis systematically evaluated the association between FGFR2 amplification status, FGFR2b protein expression, and the clinical efficacy of bemarituzumab, providing critical evidence-based support for refined patient stratification in FGFR2b-targeted therapy for gastric cancer.


Background

Bemarituzumab is a humanized monoclonal antibody targeting FGFR2b. Its efficacy has been evaluated in two global phase 3 clinical trials, FORTITUDE-101 (F101) and FORTITUDE-102 (F102), enrolling patients with FGFR2b-overexpressing advanced GC/GEJ. With extended follow-up, the overall survival (OS) benefit observed in F101 was attenuated, while F102 failed to demonstrate significant overall efficacy.

Building on these observations, the research team hypothesized that tumor FGFR2 amplification status may serve as a core biological modifier of clinical outcomes with bemarituzumab. This exploratory analysis was designed to characterize the correlation between FGFR2 amplification and FGFR2b protein overexpression, and to assess the predictive value of FGFR2 amplification for bemarituzumab efficacy.


Methods

The analysis included patients with FGFR2b-overexpressing advanced GC/GEJ from both phase 3 studies. FGFR2b protein expression in tumor tissue was assessed by immunohistochemistry (IHC) using the FGFR2-D antibody. For evaluable specimens (excluding those from China and Brazil), FGFR2 amplification status was determined by tissue next-generation sequencing (NGS, Tempus xT platform; amplification defined as copy number ≥8 with tumor purity ≥30%) and/or plasma circulating tumor DNA (ctDNA) NGS (Guardant360 Liquid assay; amplification defined as copy number ≥2.2).

In this study, FGFR2b overexpression was defined as moderate (2+) to strong (3+) membrane staining in any proportion (>0%) of tumor cells. All results presented are based on the subset of patients with FGFR2b overexpression in ≥10% of tumor cells.


Results

1. Prevalence of FGFR2 Amplification and Its Association with Protein Expression

Among patients with ≥10% FGFR2b overexpression, FGFR2 amplification (confirmed by tissue and/or ctDNA NGS) was detected in 18.9% (35/185) of patients in F101 and 15.9% (47/296) of patients in F102.

Consistent findings were observed across both studies: patients with FGFR2 amplification had significantly higher FGFR2b protein expression than those without amplification. In F101, the median percentage of tumor cells with 2+/3+ staining was 65% in the amplified group versus 20% in the non-amplified group; in F102, the corresponding values were 80% and 20%, respectively (nominal p < 0.001 for both comparisons). However, correlation analysis showed only a weak association between FGFR2b protein expression level and FGFR2 gene copy number (Spearman correlation coefficient rho < 0.3).

2. Overall Survival (OS)

Survival analysis demonstrated a more pronounced survival benefit of bemarituzumab in the FGFR2 amplification subgroup:

F101 study: Among patients with FGFR2 amplification, median OS was 19.3 months with bemarituzumab versus 8.0 months with placebo, corresponding to a hazard ratio (HR) of 0.50 (95% CI 0.22–1.12).

F102 study: Among patients with FGFR2 amplification, median OS was 16.6 months with bemarituzumab versus 8.0 months with placebo, corresponding to an HR of 0.67 (95% CI 0.34–1.32).

In contrast, the OS benefit of bemarituzumab versus placebo was markedly diminished in patients without FGFR2 amplification:

F101 study: Among non-amplified patients, median OS was 12.9 months in both the bemarituzumab and placebo groups, with an HR of 0.94 (95% CI 0.65–1.37).

F102 study: Among non-amplified patients, median OS was 17.3 months with bemarituzumab versus 14.5 months with placebo, with an HR of 0.84 (95% CI 0.61–1.15).

3. Progression-Free Survival (PFS)

The PFS benefit trend was consistent with OS findings, with a larger magnitude of benefit in the amplified subgroup:

F101 study: Among patients with FGFR2 amplification, median PFS was 8.8 months with bemarituzumab versus 5.1 months with placebo (HR 0.47, 95% CI 0.21–1.02); among non-amplified patients, median PFS was 8.1 months and 7.2 months, respectively (HR 0.91, 95% CI 0.63–1.30).

F102 study: Among patients with FGFR2 amplification, median PFS was 9.0 months with bemarituzumab versus 5.6 months with placebo (HR 0.77, 95% CI 0.40–1.49); among non-amplified patients, median PFS was 8.7 months and 6.9 months, respectively (HR 0.87, 95% CI 0.65–1.17).


Conclusions

GC/GEJ with concurrent FGFR2b protein overexpression and FGFR2 gene amplification may represent a biologically distinct tumor subtype, and patients with this molecular profile exhibit heightened sensitivity to bemarituzumab.

This finding not only accounts for the divergent efficacy outcomes across the two prior phase 3 studies, but also establishes a core rationale for the further clinical development of FGFR2b inhibitors in FGFR2-amplified gastric cancer, paving the way for refined patient stratification in the precision targeted therapy of advanced gastric cancer.